{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:46:55Z","timestamp":1790221615540,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011338","name":"AstraZeneca AG","doi-asserted-by":"publisher","award":["ESR23-22388"],"award-info":[{"award-number":["ESR23-22388"]}],"id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rmed.2025.108312","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T20:54:34Z","timestamp":1755809674000},"page":"108312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Substantial reduction in oral corticosteroid use after biologics initiation in severe asthma: An analysis based on Swiss pharmacy data"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8021-0950","authenticated-orcid":false,"given":"Pierre-Olivier","family":"Bridevaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5209","authenticated-orcid":false,"given":"Arnaud","family":"Bourdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Peytremann-Bridevaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7463-9187","authenticated-orcid":false,"given":"Van Ganse","family":"Eric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.rmed.2025.108312_bib2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1183\/09031936.00004110","article-title":"Prevalence of airflow obstruction in smokers and never-smokers in Switzerland","volume":"36","author":"Bridevaux","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.rmed.2025.108312_bib3","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1183\/09031936.04.00004904","article-title":"Asthma severity and medical resource utilisation","volume":"23","author":"Antonicelli","year":"2004","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108312_bib4","first-page":"1","article-title":"Uncovering the spectrum of healthcare resource utilization and costs across moderate to severe asthma: high-cost subgroups and impact of biologics","author":"Hwee","year":"2025","journal-title":"J. Asthma"},{"issue":"2","key":"10.1016\/j.rmed.2025.108312_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the national heart, lung, and blood institute's severe asthma research program","volume":"119","author":"Moore","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.rmed.2025.108312_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"628","key":"10.1016\/j.rmed.2025.108312_bib8","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3399\/bjgp14X682237","article-title":"National review of asthma deaths (NRAD)","volume":"64","author":"Levy","year":"2014","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.rmed.2025.108312_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105859","article-title":"One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting \u03b2(2)-agonist in UK primary care settings","volume":"162","author":"Buhl","year":"2020","journal-title":"Respir. Med."},{"issue":"6","key":"10.1016\/j.rmed.2025.108312_bib10","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.jaip.2019.12.002","article-title":"Trajectory analyses of adherence patterns in a real-life moderate to severe asthma population","volume":"8","author":"van Boven","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.108312_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/JAA.S442217","article-title":"Bronchodilator responsiveness measured by spirometry and impulse oscillometry in patients with asthma after short acting antimuscarinic and\/or Beta-2-Agonists inhalation","volume":"17","author":"van der Burg","year":"2024","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.rmed.2025.108312_bib12","doi-asserted-by":"crossref","DOI":"10.2196\/50085","article-title":"Trajectories of controller therapy use before and after asthma-related hospitalization in children and adults: population-based retrospective cohort study","volume":"9","author":"Belhassen","year":"2023","journal-title":"JMIR Public Health Surveill"},{"key":"10.1016\/j.rmed.2025.108312_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107714","article-title":"Adherence to inhaled corticosteroid therapy and treatment escalation in the Swedish adult asthma population","volume":"231","author":"Packham","year":"2024","journal-title":"Respir. Med."},{"issue":"10","key":"10.1016\/j.rmed.2025.108312_bib14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/thorax.57.10.880","article-title":"Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma","volume":"57","author":"Suissa","year":"2002","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.rmed.2025.108312_bib15","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02259-2019","article-title":"Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma","volume":"55","author":"d'Ancona","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"9","key":"10.1016\/j.rmed.2025.108312_bib16","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jaip.2023.05.044","article-title":"Impact of initiating biologics in patients with severe asthma on long-term oral corticosteroids or frequent rescue steroids (GLITTER): data from the international severe asthma registry","volume":"11","author":"Chen","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"10","key":"10.1016\/j.rmed.2025.108312_bib17","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1111\/all.16178","article-title":"Real-world biologics response and super-response in the international severe asthma registry cohort","volume":"79","author":"Denton","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.rmed.2025.108312_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.107944","article-title":"Background therapy in severe asthma on monoclonal antibody treatment in real life","volume":"237","author":"Cosini","year":"2025","journal-title":"Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108312_bib19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/resp.13730","article-title":"Rational oral corticosteroid use in adult severe asthma: a narrative review","volume":"25","author":"Chung","year":"2020","journal-title":"Respirology"},{"issue":"5","key":"10.1016\/j.rmed.2025.108312_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01486-2017","article-title":"Mortality: a neglected outcome in OCS-treated severe asthma","volume":"50","author":"Bourdin","year":"2017","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108312_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/npjpcrm.2015.26","article-title":"Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study","volume":"25","author":"Cooper","year":"2015","journal-title":"NPJ Prim Care Respir Med"},{"issue":"13","key":"10.1016\/j.rmed.2025.108312_bib22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.rmed.2025.108312_bib23","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.108312_bib24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2025.108312_bib25","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2147\/JAA.S468068","article-title":"Disease burden and access to biologic therapy in patients with severe asthma, 2017-2022: an analysis of the international severe asthma registry","volume":"17","author":"Le","year":"2024","journal-title":"J. Asthma Allergy"},{"issue":"5","key":"10.1016\/j.rmed.2025.108312_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01671-2018","article-title":"The severe heterogeneous asthma research collaboration, patient-centred (SHARP) ERS clinical research collaboration: a new dawn in asthma research","volume":"52","author":"Djukanovic","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108312_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J. Asthma Allergy"},{"issue":"164","key":"10.1016\/j.rmed.2025.108312_bib28","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0278-2021","article-title":"Biologics in severe asthma: the role of real-world evidence from registries","volume":"31","author":"Paoletti","year":"2022","journal-title":"Eur. Respir. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2025.108312_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.chest.2024.04.010","article-title":"International severe asthma registry: closer to the full picture of asthma care and outcomes?","volume":"166","author":"Van Ganse","year":"2024","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2025.108312_bib30","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.jaip.2019.02.025","article-title":"Changes in persistent asthma care and outcomes from 2006 to 2016 in France","volume":"7","author":"Belhassen","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"10.1016\/j.rmed.2025.108312_bib31","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1183\/09031936.00100113","article-title":"Asthma drug ratios and exacerbations: claims data from universal health coverage systems","volume":"43","author":"Laforest","year":"2014","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108312_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.rmed.2016.12.017","article-title":"Severe and non-severe asthma in the community: a large electronic database analysis","volume":"123","author":"Varsano","year":"2017","journal-title":"Respir. Med."},{"issue":"5","key":"10.1016\/j.rmed.2025.108312_bib33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/all.12137","article-title":"Role of comorbid conditions in asthma hospitalizations in the south of France","volume":"68","author":"Aubas","year":"2013","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.rmed.2025.108312_bib34","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.jaip.2018.12.029","article-title":"The burden of severe asthma in France: a case-control study using a medical claims database","volume":"7","author":"Bourdin","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.108312_bib35","series-title":"The Federal Swiss Coucil: Federal Act on Research Involving Human Beings","year":"2023"},{"key":"10.1016\/j.rmed.2025.108312_bib36","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/JAA.S327659","article-title":"Severe asthma in a general population study: prevalence and clinical characteristics","volume":"14","author":"R\u00f6nnebjerg","year":"2021","journal-title":"J. Asthma Allergy"},{"issue":"2","key":"10.1016\/j.rmed.2025.108312_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/03007995.2018.1528218","article-title":"Uncontrolled severe asthma: starting from the unmet needs","volume":"35","author":"Caminati","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.rmed.2025.108312_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2021.100528","article-title":"\"Real-life\" management of patients with severe asthma in the biologics era: can we do better?","volume":"14","author":"Charriot","year":"2021","journal-title":"World Allergy Organ J"},{"issue":"6","key":"10.1016\/j.rmed.2025.108312_bib39","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"59","author":"Chung","year":"2022","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2025.108312_bib40","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"Hekking","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"759","key":"10.1016\/j.rmed.2025.108312_bib41","first-page":"1979","article-title":"[Diagnostic and therapeutic approach to difficult asthma]","volume":"17","author":"Grandbastien","year":"2021","journal-title":"Rev. Med. Suisse"},{"issue":"10","key":"10.1016\/j.rmed.2025.108312_bib42","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1185\/03007990903224125","article-title":"Predictors of asthma control in everyday clinical practice in Switzerland","volume":"25","author":"Taegtmeyer","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"10.1016\/j.rmed.2025.108312_bib43","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1185\/030079906X148454","article-title":"Asthma control in Switzerland: a general practitioner based survey","volume":"22","author":"Leuppi","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.rmed.2025.108312_bib44","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1159\/000533474","article-title":"Characteristics of severe asthma patients and predictors of asthma control in the Swiss severe asthma registry","volume":"102","author":"Jaun","year":"2023","journal-title":"Respiration"},{"issue":"26","key":"10.1016\/j.rmed.2025.108312_bib45","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1716868","article-title":"Combined analysis of asthma safety trials of long-acting \u03b2(2)-Agonists","volume":"378","author":"Busse","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.rmed.2025.108312_bib46","doi-asserted-by":"crossref","first-page":"904","DOI":"10.7326\/0003-4819-144-12-200606200-00126","article-title":"Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths","volume":"144","author":"Salpeter","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.rmed.2025.108312_bib47","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1164\/rccm.201709-1940PP","article-title":"Food and drug administration-mandated trials of long-acting \u03b2-Agonist safety in asthma. Bang for the buck?","volume":"197","author":"Suissa","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.rmed.2025.108312_bib48","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.arbres.2022.12.006","article-title":"Beta-agonist use and increased asthma mortality: reality or fiction?","volume":"59","author":"Zhao","year":"2023","journal-title":"Arch. Bronconeumol."},{"issue":"5","key":"10.1016\/j.rmed.2025.108312_bib49","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03130-2021","article-title":"Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients","volume":"60","author":"Humbert","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108312_bib50","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202412-2431VP","article-title":"Stop the asthma treatment elevator, we need to get off","author":"Bush","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125003750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125003750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:26:37Z","timestamp":1772825197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125003750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":48,"alternative-id":["S0954611125003750"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108312","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Substantial reduction in oral corticosteroid use after biologics initiation in severe asthma: An analysis based on Swiss pharmacy data","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108312"}}